We're designers and problem solvers by nature. Addressing unmet needs through novel but practical solutions is what drives our product pipeline.
Xeris is currently progressing with clinical studies in several areas, including:
- Management of severe hypoglycemia.
- Post-bariatric hypoglycemia (PBH).
Xeris has a robust pipeline across its ready-to-use portfolios
Through a series of grant-supported collaborations, Xeris is exploring additional uses for ready-to-use glucagon in mild-to-moderate hypoglycemia. Additionally, Xeris is evaluating stable, liquid glucagon as a combination therapy inside a physiological, closed-loop, bi-hormonal artificial pancreas.
In non–glucagon-based research projects, clinical studies are underway for the treatment of acute repetitive seizures (ARS).
We are proud to announce that as of October 5, 2021,
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc
are subsidiaries of Xeris Biopharma Holdings, Inc.
Not opening? Check to see you have pop-ups enabled or copy link below in a new window.https://ir.xerispharma.com/